Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma

Claudio Cerchione1 · Davide Nappi2 · Giovanni Martinelli1

Received: 19 November 2020 / Accepted: 30 April 2021 / Published online: 14 May 2021
© The Author(s) 2021

Abstract
Multiple myeloma (MM) survival rates have been substantially increased thanks to novel agents that have improved survival outcomes and shown better tolerability than treatments of earlier years. These new agents include immunomodulating imide drugs (IMiD) thalidomide and lenalidomide, the proteasome inhibitor bortezomib (PI), recently followed by new generation IMiD pomalidomide, monoclonal antibodies daratumumab and elotuzumab, and next generation PI carfilzomib and ixazomib. However, even in this more promising scenario, febrile neutropenia remains a severe side effect of antineoplastic therapies and can lead to a delay and/or dose reduction in subsequent cycles. Supportive care has thus become key in helping patients to obtain the maximum benefit from novel agents. Filgrastim is a human recombinant subcutaneous preparation of G-CSF, largely adopted in hematological supportive care as “on demand” (or secondary) prophylaxis to recovery from neutropenia and its infectious consequences during anti-myeloma treatment. On the contrary, pegfilgrastim is a pegylated long-acting recombinant form of granulocyte colony-stimulating factor (G-CSF) that, given its extended half-life, can be particularly useful when adopted as “primary prophylaxis,” therefore before the onset of neutropenia, along chemotherapy treatment in multiple myeloma patients. There is no direct comparison between the two G-CSF delivery modalities. In this review, we compare data on the two administrations’ modality, highlighting the efficacy of the secondary prophylaxis over multiple myeloma treatment. Advantage of pegfilgrastim could be as follows: the fixed administration rather than multiple injections, reduction in neutropenia and febrile neutropenia rates, and, finally, a cost-effectiveness advantage.

Keywords Pegfilgrastim · Multiple myeloma · G-CSF · Supportive care · Febrile neutropenia

Introduction
Multiple myeloma (MM) is a clonal plasma cell disorder hallmarked by the uncontrolled proliferation of plasma cell-producing monoclonal proteins that leads to direct and indirect organ damage [1]. Thus, the typical clinical picture of a patient with MM may be represented by renal failure, bone pain and fractures, hypercalcemia, anemia, or other types of cytopenia. MM accounts for about 1% of all cancers and 13% of hematological tumors. It is the second most common hematological malignancy, with an incidence of 6.2 cases per 100,000 individuals [1, 2] with a median range of age at diagnosis of 65–74 years [3]. Although it is not a curable disease, MM survival rates have been substantially improved thanks to the introduction of novel agents such as immunomodulating imide drugs (IMiD) thalidomide and lenalidomide, and the proteasome inhibitor (PI) bortezomib, all of which show improved tolerability and outcome with respect to drugs of earlier years. The therapeutic panorama has further improved following the approval of new generation IMiD pomalidomide, monoclonal antibodies daratumumab and elotuzumab, and next generation PI carfilzomib and ixazomib. [4–6]. However, the advantages of this highly promising therapeutic scenario in a disease that had a poor prognosis until relatively recently must be balanced with the toxicity profile of these compounds. Although these new and newer agents are not “chemotherapy” in the strictest sense of the word, they induce many adverse events that can reduce patient quality of life so severely that treatment...
Discontinuation is needed. In addition to the specific toxicities of each novel and very novel agent currently used to treat MM, mild to severe neutropenia (and associated febrile neutropenia [FN]) is a constant problem [7]. Severe neutropenia leads to a significant risk of harmful, albeit not life-threatening, bacterial, fungal, or mixed infections in hematological malignancies. Given that MM is (considered) a chronic disease of the elderly, with recurrent remission and relapse, infections remain the main cause of death [8]. Preventing neutropenia and febrile neutropenia is thus one of the main aims of ancillary and supportive treatments for patients with MM. Antibiotic prophylaxis (mainly quinolones) is widely used in clinical practice but EORTC guidelines do not recommend its use in hematological and solid tumors as there is a lack of evidence of its efficacy [9, 10]. Thus, the prophylactic use of quinolones should be limited to high-risk patients who are expected to have severe-grade and prolonged neutropenia while undergoing treatment [11].

Filgrastim is a recombinant human G-CSF that stimulates the activation, proliferation, and differentiation of neutrophil progenitor cells. It has been shown to reduce chemotherapy-related neutropenia, lower the incidence of FN, and decrease the need for hospitalization and intravenous antibiotics [12]. Given its short half-life, multiple daily subcutaneous injections of filgrastim are normally required before an optimal neutrophil count is reached. By increasing molecular size through the process of PEGylation, pegfilgrastim has overcome this major pharmacokinetic issue, reducing the plasma clearance rate of filgrastim and prolonging the half-life [13]. The resulting effect is a dramatic reduction in the rate of administration to one subcutaneous injection per cycle of chemotherapy [14].

**Neutropenia and FN in multiple myeloma**

Neutropenia is defined by Common Terminology Criteria for Adverse Events (CTCAE) as any decrease in absolute neutrophil count (ANC) below 1500/mm³, where moderate and severe neutropenia (grade 3–4) are defined as an ANC < 1000–500/mm³ and < 500/mm³, respectively (CTCAE version 5.0). Moderate and severe neutropenia, especially if prolonged, can lead to FN, with ANC < 1000/mm³ and a single temperature of > 38.3 °C (101.4°F) or a sustained temperature of ≥ 38 °C (100.4°F) for more than 1 h (CTCAE version 5.0). A direct correlation between a reduced number of neutrophil cells and an increased risk of infection (mainly bacterial and fungal) in MM patients is a fundamental problem in clinical practice [15]. Although neutropenia-related infections can, in themselves, be a severe and potentially life-threatening condition, they may also lead to a delay in the administration of chemotherapy, thus affecting the treatment efficacy and the final clinical outcome. Neutropenia in MM, as in other malignancies, is mainly due to the immunosuppressive and immunomodulating effect of treatment (also novel non-conventional chemotherapeutic compounds) and to the damage caused to mucosal barriers [16]. In addition, MM patients are often immunocompromised by the malfunctioning of immunocompetent cells (B, T, and dendritic cells) caused by clonal plasma cell expansion, constitutional immunosuppression (elderly and frail patients), and intensive and prolonged corticosteroid treatment [8]. In the era of immunomodulating agents, the incidence of infections, especially of bacterial and viral etiology, seems to follow a pattern with two major peaks: at diagnosis/induction and at relapse of disease [17]. A 2015 retrospective evaluation also reported a tenfold higher risk of specific infections, such as pneumonia or septicemia, in the first year after diagnosis of MM, with no major improvements in these rates following the introduction of novel agents [18]. The incidence of neutropenia and FN obviously varies according to the type of treatment regimen adopted. The oldest and/or more aggressive chemotherapeutic agents (or combinations) show the highest rates of severe neutropenia and infections. High-dose melphalan followed by autologous stem cell transplantation (ASCT), the treatment recommended for young and fit patients, has severe neutropenia and infection rates up to 77% and 30%, respectively [19–21]. Other chemotherapeutic combinations used only in highly aggressive disease or in multiple refractory patients, such as VTD-PACE (bortezomib, thalidomide, dexamethasone and cisplatin, doxorubicin, cyclophosphamide, and etoposide) or PACE (cisplatin, doxorubicin, cyclophosphamide, and etoposide) show neutropenia rates of 79% and 83%, respectively, and FN rates of 26% and 33%, respectively [22, 23]. Novel agents such as thalidomide, lenalidomide, and, more recently, pomalidomide (IMiD) are now the backbone of treatment for newly diagnosed and relapsed MM. Neutropenia is one of the most common and predictable adverse events occurring during the use of lenalidomide (along with dexamethasone) and is often managed by treatment discontinuation, dose modulation, and/or G-CSF [24, 25]. The rates of neutropenia and infections from lenalidomide vary according to the dose of dexamethasone and combination compound used, ranging from 32 to 41% and 8 to 22%, respectively [26]. Pomalidomide is a new generation IMiD indicated for the treatment of relapsed/refractory MM (rrMM). Like thalidomide, the most evident adverse event associated with pomalidomide is neutropenia (up to 50% of patients), whereas the rate of associated infections (pneumonia) is lower in proportion (about 13%) [27, 28]. Pomalidomide is often used in heavily pretreated patients who have highly compromised bone marrow function, thus explaining the higher incidence of neutropenia with respect to lenalidomide. It is manageable with dosage modification or treatment withdrawal, and G-CSF support, especially in...
the first cycles [29]. The first-in-class PI bortezomib, used in association with dexamethasone or other associated molecules (melphalan, lenalidomide), now plays a key role in both newly diagnosed MM (eligible/not eligible) and refractory/relapsed disease [30]. The rates of severe neutropenia and FN are notably lower than those of IMiD, i.e., up to 11% and < 1%, respectively, with very low rates of treatment discontinuation [31]. Carfilzomib, a second-generation PI approved for use in a rrMM setting, induces grade > 3 neutropenia in around 30% of cases, but this rate is probably related to the lenalidomide (and dexamethasone) associated with the regimen [32]. Ixazomib, a newer, orally available PI combined with lenalidomide-dexamethasone, leads to neutropenia rates of about 22%, with a very low incidence of discontinuation for infections [33]. Daratumumab, a newly available anti-CD38 approved for use in rrMM combined with lenalidomide or bortezomib, shows neutropenia rates of about 52% and 12.8%, respectively [34, 35]. Of note, lenalidomide is the leading cause of neutropenia when comparing two regimens containing or not this IMiD. Finally, elotuzumab, a new generation monoclonal antibody directed against SLAMF7 protein, when administered together with lenalidomide for refractory/relapsed MM, has been shown to induce grade > 3 neutropenia rates of 35.5% [36]. Among the drugs approved for use in MM, all IMiD, bortezomib and daratumumab, come with “special warnings” about the development of neutropenia and FN [7]. It can be concluded that the introduction of these so-called novel agents did not reduce the incidence of neutropenia because of the strong intrinsic neutropenic effect of IMiD (lenalidomide and pomalidomide) and also because other novel agents without a significant innate neutropenic innate effect (such as monoclonal antibodies or PI) are often used in combination with IMiD.

Pharmacology of pegfilgristim

The recombinant methionyl human G-CSF filgrastim, introduced into clinical practice in 1991, works mainly by inducing the proliferation and differentiation of committed progenitor cells of the granulopoietic lineage into functionally mature neutrophils [37]. When administered subcutaneously, filgrastim can induce a rapid increase in the ANC within 24 h, requiring continuous daily injections to reach an adequate ANC level (about 5 days) [38]. Filgrastim pharmacokinetics, in particular its clearance, is inversely related to the ANC. The mean half-life is 4.7 h at an ANC of 0 but < 2 h when the ANC is > 17.0 × 10^9/L [39]. These data suggest a complex physiological model of filgrastim clearance, with two main pathways. Like other cytokines and growth factors (thrombopoietin, erythropoietin, etc.) whose production is inhibited by an increase in the cells that are biologically targeted by them in a negative feedback manner, G-CSF synthesis is reduced when the ANC increases, as shown in preclinical and clinical models [40–43]. There is in vitro evidence that a G-CSF clearance process is directly mediated by a specific receptor expressed on the surface of mature neutrophils [44]. In addition to the mechanism directly involving neutrophils, G-CSF removal is also governed by renal excretion [45, 46]. Thus, there are two main pathways that determine G-CSF removal and half-life shortening: renal function, capable of constant renal clearance even with a very low ANC, and a modulatory (and theoretically saturable) pathway mediated by the number of circulating neutrophils. The consequences of this complex clearance mechanism are that patients require subsequent daily subcutaneous injections of filgrastim to obtain an adequate ANC level and that there is no universally standardized schedule of administration (may be administered either every day or every other day) [47]. The introduction of the pegylated form, pegfilgrastim, has overcome this clinical issue thanks to covalent conjugation of proteins with polyethylene–glycol (PEG), a standard pharmaceutical strategy used to prolong half-life and improve the clinical benefit of different kinds of molecules with biological activity (e.g., peg-interferon, peg-asparaginase) [48–50]. Pegfilgrastim has the same biological properties as filgrastim, including the stimulation of the proliferation and differentiation of neutrophil precursors into mature cells. It also has the advantage of a longer-lasting half-life, leading to a single administration per cycle thanks to diminished renal clearance because of the reduced permeability of glomerular barrier by a larger molecule [48, 51, 52].

Pegfilgrastim as primary prophylaxis in multiple myeloma

Pegfilgrastim is an effective mobilizing agent during ASCT for different hematological neoplasms, including patients with MM undergoing this procedure, but its role in this setting is outside the scope of the present review [53–55]. It has also become widely used in Europe thanks to the fact that it can be administered in a single subcutaneous injection at a fixed time (at least 24 h after therapy) and at a fixed dose (6 mg), which can substantially improve patient compliance to receive this fundamental supportive measure. Moreover, although no direct comparisons have been made, there is evidence to suggest that pegfilgrastim is superior to filgrastim in reducing neutropenia and FN [56, 57]. Like filgrastim, there are two alternative strategies for its use in MM, i.e., as a primary and secondary prophylaxis [58]. The latter or “on demand” prophylaxis is only recommended for treatment regimens with low rates of neutropenia and FN and is based on multiple injections of filgrastim when severe neutropenia
or neutropenia-related symptoms appear [59]. For many clinicians, this strategy may seem inadequate to protect frail patients, as MM patients often are, from the risk of severe infection. Pegfilgrastim-based primary prophylaxis is highly recommended during regimens at high risk of causing severe neutropenia (expected incidence > 20%), i.e., lenalidomide-containing regimens or pomalidomide-containing regimens [58]. This strategy is also highly recommended for patients undergoing treatments with an intermediate low risk of neutropenia (e.g., bortezomib-based triple-drug regimens) and for those harboring risk factors for neutropenia (e.g., age > 65 years, comorbidities, low performance status, poor nutritional status) [58]. Primary prophylaxis is also recommended for patients with an expected rate of FN > 20% [59]. The use of primary prophylaxis in MM starting from the first courses of treatment reduces the risk of severe infections, which is highest in the first 2 months, and decreases the need for premature dose adjustment or treatment discontinuation, conditions that could potentially impede an initial and rapid breakdown of disease burden. Primary prophylaxis with pegfilgrastim has been investigated less frequently than the use of the G-CSF in ASCT. Three trials investigating a lenalidomide-based regimen, i.e., regimens harboring a high risk of neutropenia and infections, used pegfilgrastim for primary prophylaxis. The German Myeloma Study Group (DSMM) conducted a phase 1–2 trial exploring the efficacy and tolerability of the lenalidomide, adriamycin, and dexamethasone combination in rrMM, delivered as a 28-day cycle [60]. Pegfilgrastim 6 mg was administered on the 6th day of each cycle, and after four cycles, the dose level of the drugs was evaluated without the use of G-CSF support. Primary support with pegfilgrastim enabled the maximum tolerated dose of lenalidomide (25 mg) to be reached, with neutropenia and infection rates of 48% and 10.5%, respectively (grades 3 and 4). The possibility of increasing the maximum tolerated dose level of lenalidomide resulted in a better response, in terms of ORR [60]. Neutropenia (grade 3–4) was also explored in a prospective observational study in which rrMM patients underwent treatment with lenalidomide-dexamethasone [61]. Neutropenia and febrile neutropenia rates were 31% and 3%, respectively, but the significance of primary prophylaxis with pegfilgrastim was weak as this specific G-CSF support modality was only used in 8% of patients. A prospective, multicenter phase 2 trial was conducted to assess the efficacy and safety of the bendamustine-lenalidomide-dexamethasone combination in rrMM [62]. Pegfilgrastim was administered to 68% of patients as primary prophylaxis at a dose of 6 mg on day 3 of each 28-day cycle. In this regimen, where another strong neutropenia-inducing drug such as bendamustine was added to lenalidomide, the high rate of grade 3–4 neutropenia (74%) and other hematological toxicities was concerning, and pegfilgrastim supportive care was fundamental to ensuring the adequate delivery of the planned treatment. These are not data from a study whose main objective was to assess primary prophylaxis with pegfilgrastim, but rather are ancillary information obtained from the overall data on safety. More insights into pegfilgrastim prophylaxis can also be obtained from real-life surveys. In an observational study, 41 patients with heavily pre-treated rrMM exposed to multiple types of anti-myeloma agents underwent primary prophylaxis with pegfilgrastim 6 mg on day 3 from the second course of treatment onwards after a first cycle in which multiple injections of filgrastim were administered [63]. Pegfilgrastim proved superior to filgrastim in terms of both quality of response to neutropenia (evaluating absolute neutrophils at nadir) and duration of neutropenia, which was shorter in the cycles supported by pegfilgrastim [63]. This led to a reduction in the rate of neuropenia and infection and enabled the established treatment schedule to be delivered to a cohort of very frail patients. Similarly, another cohort of 47 rrMM patients given bendamustine-bortezomib-dexamethasone as salvage therapy was studied to evaluate the superior efficacy of pegfilgrastim prophylaxis over filgrastim prophylaxis in this regimen with its potentially high risk of neutropenia [64]. Twenty-four patients underwent pegfilgrastim 6 mg on day 4, while the remaining 23 received “on demand” filgrastim when ANC dropped < 1000 cells/mL. Prophylaxis with pegfilgrastim was significantly associated with lower FN-related chemotherapy disruption rates (8.3% vs 17.3% in the pegfilgrastim and filgrastim groups, respectively) and fewer FN-related days in hospital (0 vs 15 days, respectively). There was also a decrease in the rate of infection that enabled the scheduled chemotherapy to be administered, without the need for (lengthy) treatment discontinuation [65]. In these clinical experiences, pegfilgrastim is tolerated as well as if not better than filgrastim, with the classic adverse events associated with G-CSF (mild fever and bone pain, easily manageable with paracetamol) [63, 64]. Table 1 provides an overview of the reported studies.

Conclusions

Primary prophylaxis with pegfilgrastim in MM is feasible, safe, and effective. Many clinical data, although mostly observational, address the superiority of pegfilgrastim prophylaxis over filgrastim, especially in neutropenia high-risk treatment [65, 66]. However, the lack of prospective trials in this field has prevented guidelines from being established for clinicians. The choice between the two delivery modalities of G-CSF support, i.e., primary prophylaxis or secondary prophylaxis, is still based on clinical and non-clinical factors. There are several factors pointing to the advantage of primary prophylaxis with pegfilgrastim over “on demand” filgrastim: (1) the fact of having one fixed
Table 1  An overview of the reported studies

| References          | Study design                  | Patients and treatment                              | PEG schedule                  | Results                                                                 | Comments                                                                 |
|---------------------|-------------------------------|-----------------------------------------------------|--------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Knop et al. [60]    | Phase1/trial, MTD evaluation  | 190 RRMM patients undergoing RAD                    | Pegfilgrastim 6 mg s.c. day + 6 as primary prophylaxis | Grade 3–4 neutropenia and infections rates were 48% and 10.5%, respectively | PEG prophylaxis led to better tolerability of lenalidomide-related neutropenia, thus providing better outcomes |
| Leleu et al. [61]   | Prospective, observational    | 198 MM patients undergoing lenalidomide plus dexamethasone | Only 16 patients on primary prophylaxis with PEG (no dose reported) | 12 patients had a reduction of lenalidomide exposure and long GCSF course | Some patients would have been well tolerated lenalidomide with PEG prophylaxis instead of GCSF support |
| Mey et al. [62]     | Prospective phase 2           | 50 RRMM patients undergoing bendamustine-lenalidomide-dexamethasone | Pegfilgrastim 6 mg s.c. day + 3 as primary prophylaxis | Grade 4 neutropenia 34% of patients                                      | PEG prophylaxis limited bendamustine toxicity, leading to better outcome |
| Cerchione et al. [63]| Observational                 | 41 heavily pre-treated RRMM patients supported with GCSF or PEG | Pegfilgrastim 6 mg s.c. day + 3 | Neutropenia duration was shorter and quantitatively reduced in PEG primary prophylaxis setting vs GCSF on demand setting | PEG provided better tolerability of treatment regimens, with less treatment disruption neutropenia or FN-related |
| Cerchione et al. [64]| Observational                 | 47 heavily pre-treated RRMM patients supported with GCSF or PEG while on bendamustine | Pegfilgrastim 6 mg s.c. day + 4 | Neutropenia duration was shorter and quantitatively reduced in PEG primary prophylaxis setting vs GCSF on demand setting | PEG provided better tolerability of treatment regimens, with less treatment disruption neutropenia or FN-related |
administration rather than multiple injections, which positively impacts quality of life; (2) the possibility of a more effective prevention of infections, the main cause of death in MM patients; and (3) the reduction in overall costs (days in hospital, use of anti-infective drugs, and other diagnostic and therapeutic measures for severe infection) for patients receiving supportive care with pegfilgrastim. Overall, expert opinion on induction of primary prophylaxis in multiple myeloma recommends the adoption of this strategy in case of high-risk neutropenia treatments, such as triplets lenalidomide-containing regimens, or in low/intermediate-risk treatments plus other risk factors [59]. Actually, these indications on pegfilgrastim use are still valid, but probably, when feasible, should be also extended to majority of patients due to the clinical and cost-effectiveness advantages abovementioned. Still, probably, new observational or prospective trials are needed in view of the rapid development and spread of everyday clinical practice of the use of plenty of new anti-myeloma agents that deserves adequate supportive strategy when combined with lenalidomide or, perhaps, as single agents such as pomalidomide or daratumumab.

Acknowledgements The authors thank Gráinne Tierney for editorial assistance.

Author contribution All authors have written and approved the final version of the manuscript.

Declarations

Ethics approval N/A

Consent to participate N/A

Consent for publication N/A

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060

2. Seigl RL, Miller KD, Jemal A (2016) Cancer Statistics. 2016. CA Cancer J Clin 66(7):30

3. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF et al (2016) SEER Cancer Statistics Review, 1975-2013. National Cancer Institute, Bethesda

4. Fonseca R, Abouzaid S, Bonafede M et al (2017) Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia 31(9):1915–1921

5. Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111(6):2962–2972

6. Harousseau JL, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645–2654

7. Ludwig H, Delforge M, Facoet T et al (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 32(7):1542–1560

8. Nucci M, Anaisie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49(8):1211–1225

9. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32

10. Vesole DH, Oken MM, Heckler C et al (2012) Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia 26(12):2517–2520

11. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431

12. Brampton JE, Lee CR, Filgrastim Faulds D (1994) A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48(5):731–760

13. Delgado C, Francis GE, Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9(3–4):249–304

14. Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62(8):1207–1213 (discussion 1214–5)

15. Palumbo A, Bladé J, Boccadoro M et al (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12(1):5–11

16. Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 1(40 Suppl 4):S240–S245

17. Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA (2015) Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171:100–108

18. Blimark C, Holmberg E, Melloqvist UH et al (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100(1):107–113

19. Palumbo A, Cavallò F, Gay F et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):995–995

20. Palumbo A, Bringhen S, Bruno B et al (2010) Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicentre phase 3 study. Blood 115(10):1873–1879

21. Gay F, Oliva S, Petrucci MT et al (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16(16):1617–1629
22. Muchtar E, Ram R, Raanani P et al (2014) First line and salvage therapy with total therapy 3-based treatment for multiple myeloma: an extended single center experience. Leuk Res 38(12):1401–1406

23. Isola I, Granell M, Marti JM et al. PACE as salvage therapy for relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 15:e300–e301. https://doi.org/10.1016/j.clml.2015.07.009

24. Lonial SB, Swern R, Weber AS et al 2009 “Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone.” Blood, vol. 114, abstract no. 2879. https://doi.org/10.1182/blood.V114.22.2879.2879

25. Pérez Persona E, Mesa MG, García Sánchez PI et al (2011) Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther 28:11–16

26. Palumbo A, Miguel JS, Sonneveld P et al (2008) Lenalidomide: a new therapy for multiple myeloma. Cancer Treat Rev 34:283–291

27. Miguel JS, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055–1066

28. Dimopoulos MA, Palumbo A, Corradini P et al (2016) Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 128(4):497–503

29. Dimopoulos MA, Leleu X, Palumbo A et al (2014) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573–1585. https://doi.org/10.1038/leu.2014.60

30. Kouroukis TC, Baldassarre FG, Haynes AE et al (2014) Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol 21(4):e573–e603

31. San Miguel J, Bladé J, Boccadoro M et al (2006) A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11(1):51–61

32. Stewart AK, Rajkumar SV, Dimopoulos MA et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152

33. Moreau P, Masszi T, Grzasko N et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634

34. Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331

35. Palumbo A, Chanan-Khan A, Weis K et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766

36. Dimopoulos MA, Lonial S, White D et al (2017) Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 178(6):896–905

37. Hollingshead LM, Goa KL (1991) Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42(2):300–330

38. Morstyn G, Campbell L, Lieschke G et al (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7(10):1554–1562

39. Kearns CM, Wang WC, Stute N et al (1993) Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 123(3):471–479

40. Emmons RV, Reid DM, Cohen RL et al (1996) Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87(10):4068–4071

41. Cazzola M, Guarnone R, Cerani P et al (1998) Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91(6):2139–2145

42. Layton JE, Hockman H, Sheridan WP et al (1989) Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74(4):1303–1307

43. Takakati H, Soda H, Fukuda M et al (1996) Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antiimcrob Agents Chemother 40(4):988–991

44. Molineux G, Kistler O, Bridell B et al (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27(12):1724–1734

45. Kuwabara T, Ishikawa Y, Kobayashi H et al (1995) Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharm Res 12(10):1466–1469

46. Fukuda M, Oka M, Ishida Y et al (2001) Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients. Antimicrob Agents Chemother 45(7):1947–1951

47. Sohn BS, Jeong JH, Ahn JH et al (2019) A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. Invest New Drugs 38:866–873. https://doi.org/10.1007/s10637-019-00863-8

48. Malik F, Delgado C, Knsli C et al (1992) Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Exp Hematol 20:1028–1035

49. Yoshimoto T, Nishimura H, Saito Y et al (1986) Characterization of polyethylene glycol-modified Lasparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res 77:1264–1270

50. Bailon P, Palleroni A, Schaffer CA et al (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C. Bioconjugate Chem 12:195–202

51. Allen RC (2002) Ex vivo half-life of neutrophils from healthy human subjects pre and post treatment with daily filgrastim or single-dose pegfilgrastim. Blood 100:A918

52. Molineux G (2004) The design and development of pegfilgrastim (PEG-rmfHuG-CSF, Neulasta). Curr Pharm Des 10(11):1235–1244

53. Amgen Inc, Thousand Oaks, California. Physician Package Insert Neulasta™ (Pegfilgrastim). 2002

54. Kobbe G, Bruns I, Fenk R et al (2009) Pegfilgrastim for PBSBC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 43:669–677

55. Kim MG, Han N, Lee EK et al (2015) Pegfilgrastim vs filgrastim in PBSBC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant 50(4):523–530

56. Pfeil AM, Allcott K, Pettengell R et al (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525–545

57. Cooper KL, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following
chemotherapy: systematic review and meta-analysis. BMC Cancer 23(11):404

58. Palumbo A, Bladé J, Boccadoro M et al (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12(1):5–11

59. Smith TJ, Bohlke K, Armitage JO (2015) Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Oncol Pract 11(6):511–513

60. Knop S, Gerecke C, Liebisch P et al (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18):4137–4143

61. Leleu X, Terpos E, Sanz RG et al (2016) An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). Am J Hematol 91(8):806–811

62. Mey UJ, Brugger W, Schwarb H et al (2017) Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 176(5):770–782

63. Cerchione C, Catalano L, Pareto AE et al (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301–302

64. Cerchione C, Catalano L, Peluso I et al (2016) Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. Support Care Cancer 24(12):4835–4837

65. Cerchione C, De Renzo A, Nappi D et al (2019) Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support. Support Care Cancer 27(5):1587–1588. https://doi.org/10.1007/s00520-019-4651 (Epub 2019 Jan 23)

66. Leleu X, Gay F, Flament A, Allcott K, Delforge M (2018) Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? Ann Hematol 97(3):387–400

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.